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1. Introduction 
Erectile dysfunction (ED) is defined as the persistent or repeated inability to achieve and/or 
maintain an adequate erection to accomplish a complete and satisfactory sexual activity. The 
term ED defines more accurately the nature of such dysfunction than the term impotence 
(National Institutes of Health (NIH) Consensus Conference, 1993; World Health 
Organization (WHO), 2000). ED manifests itself in the general population of adult males and 
increases with age. But it is more pronounced in individuals who suffer from diabetes, 
cardiovascular and metabolic problems. ED is one of the chronic complications of diabetes 
mellitus (DM), so the prevalence rate is very high in this group of men, and is one of the 
medical affectations with greatest impact on the quality of life of these patients. Because of 
the characteristic physiopathological alterations of DM, the damage caused mainly to the 
nervous and circulatory system favors the increased prevalence of ED (Kadioglu et al., 1994; 
Romero et al., 1997). In this chapter we discuss some aspects related to the epidemiology of 
ED and its prevalence in DM subjects, as well as the physiopathological mechanisms 
involved in this condition.  
2. Epidemiology of ED 
2.1 Epidemiology of ED in the general population 
It has been estimated that ED affects around 100-150 million men worldwide and it is 
expected an increase of 322 million by 2025 (Bloomgarden et al., 1998; Laumann et al., 1999); 
being DM one of the main causes. It is important to note that ED is also reflected in 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
70
conditions that frequently coexist with DM, such as hypertension and cardiovascular 
disease (Benet & Melman, 1995). Epidemiological studies clearly show the high prevalence 
of this pathology. According with a number of studies, variables such as and the 
methodology employed, the estimated prevalence of ED varies from 19% to 75%. The data 
also showed that in addition to age, as an important factor, others such as lifestyle, food and 
tobacco consumption are highly associated to ED. It is estimated that the prevalence of ED 
varies according to the age of the population from 39% at the age of 40 years to 75% in men 
aged 80 years (Morley, 1986). In the Massachusetts Male Aging Study (MMAS), it was noted 
that the prevalence rate of ED of any grade was 52% (17% classified as a minimum, 25% 
moderate, and 10% severe) (Feldman et al., 1994). In another study performed in Spain 
known as EDEM [by its Spanish acronym: Epidemiología de la Disfunción Eréctil 
Masculina, (The Epidemiology of Male ED)], it was noted that the 19% of men between 25 
and 70 years old have some degree of ED (16% classified as minimum, 2% moderate, 1% 
severe). This prevalence increases with age (8.6% in males aged from 25 to 39 years, 13.7% 
aged 40-49 years, 24.5% between 50 and 59 years, and 49% in people aged from 60 to 70 
years) (Martin-Morales et al., 2001). Further information can be found in the work carried 
out by Kubin et al., in which they describe other several studies about the incidence of ED 
made around the world (Kubin et al., 2003). 
2.2 Prevalence of ED in the diabetic population 
Prevalence of ED is significantly higher in DM when compared to that found in the general 
population. The ED is associated with an increase in age (Fedele et al., 2001; McCulloch et al, 
1980; Roth et al., 2003), poor metabolic control (Roth et al., 2003), time of evolution of DM 
(Klein, 1996; Roth, 2003), smoking (Bortolotti  et al, 2001), consumption of alcoholic 
beverages, neurological damage (Lundberg et al., 2001), depression (Fedele et al., 2000), use 
of some drugs (Kleinman et al., 2000) and microvascular complications (Romeo et al., 2000) 
among other factors. Diabetic patients, with an inadequate control of their glycemic status, 
chronically suffer from neurological and vascular damages of penile smooth muscle, 
disruptions of endothelial function, a sustained increase in oxidative stress, formation of 
advanced glycation end-products, among others, all closely related to the physiology of 
erection. All these aspects are reviewed in detail in later sections of this chapter. 
Epidemiological data show that the population of men with DM is more likely to develop ED. 
Data reported about ED in this population show a prevalence rate ranging from 35% to 78% 
depending on the age and general metabolic state of patients analyzed. In a study performed 
in 541 DM men aged 20-59 years, a prevalence rate of 35% of ED, and mainly attributed to 
microangiopathy; however, as mentioned before other factors such as age, type of treatment: 
oral hypoglycemic agents or insulin, the presence of retinopathy, symptomatic peripheral 
neuropathy, and symptomatic autonomic neuropathy (McCulloch et al., 1980) are also highly 
associated. Other studies report higher prevalence rates of 78%, of which 6% are mild, 36% 
moderate, and 36% severe. In this same study, it was found that the patients with non-insulin 
dependent diabetes that suffered of ED, had associated higher cardiovascular risks compared 
with the diabetic patients who did not have ED. Likewise, it was observed that the increase in 
cardiovascular risk factors is closely related to the severity of ED in diabetic patients (Meena et 
al., 2009). These elements suggest that ED is a common problem in diabetic patients and is a 
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direct consequence of an inadequate control of metabolic state in general and particularly of 
the glycemic state. ED has a multifactorial etiology but an appropriate diabetic patient's 
metabolic control is the best way to prevent this chronic complication of DM. 
2.3 Prevalence of ED among patients with type-1 and type-2 DM 
It is unclear whether erectile disorder is more common among men with non-insulin 
dependent diabetes (type-2, T2DM, late onset) or those with insulin-dependent diabetes 
(type-1, T1DM, early onset). Only a few studies include a prevalence of erectile disorder by 
diabetic type. In this regarding, one study reported that men with elevated body mass index 
(BMI) and T1DM showed a significantly higher risk of ED than men with elevated BMI and 
T2DM. The same study also showed that the age-adjusted prevalence of ED was higher in 
men with T1DM (51%) than with T2DM (37%) (Fedele et al., 2000). But Miccoli et al., found 
that 40% and 52% of insulin-dependent and non-insulin dependent DM participants 
respectively had impotence (Miccoli et al., 1987). Fedele et al., in 2001 also reported that the 
incidence of ED in Italian men with diabetes was higher in T2DM than in T1DM (74 versus 
45 cases per 1,000 person-years) (Fedele et al., 2001). 
3. Basic mechanism of penile erection 
Stimuli that can lead to penile erection include tactile stimuli to the penis and genitalia which 
will produce a reflex erection, while erotic stimuli, whether visual, auditory, olfactory or 
imaginative also produce penile erection by a mechanism which involves the paraventricular 
nucleus and medial preoptic area of the hypothalamus. A third mechanism is involved in the 
production of nocturnal erections that occur in all men during REM sleep (Eardley, 2002). The 
degree of contraction of the corpus cavernosum smooth muscle and the functional state of the 
penis is determined by the balance between proerectile and antierectile mechanisms that 
operate physiologically in the penis. Vasoconstriction maintains the penis in the flaccid state.  
Erectile function is dependent on relaxation of the cavernous smooth muscle, and its 
mechanism of action is mediated by Nitric Oxide (NO). NO synthesized from L-arginine is the 
key mediator of endothelium-dependent smooth muscle relaxation, and likewise it is the key 
mediator of penile erection. After any stimulation, NO is released from non-adrenergic non-
cholinergic (NANC) nerves through activation of neuronal nitric oxide synthase (nNOS). 
Binding of NO to soluble guanylate cyclase increases cyclic guanosine monophosphate 
(cGMP) levels and cGMP-dependent protein kinase-1 (PKG-1) activity, leading to smooth 
muscle cell relaxation and cavernosal dilation. Subsequent hemodynamic changes such as 
increased arteriolar shear flow stimulate the phosphatidylinositol-3-kinase/protein kinase B 
(Akt) pathway leading to activation of endothelial nitric oxide synthase (eNOS) in penile 
endothelium and further NO release. Occlusion of venous outflow is also required for 
sinusoidal filling and the maintenance of high intracavernosal pressure and erection. This 
veno-occlusion is achieved by the compression of the emissary veins that lie between the 
tunica albuginea and the expanding sinusoidal tissue (Hidalgo-Tamola & Chitaley, 2009).  
Since erection is a complex process that involves the participation of vascular, endocrine, 
cellular and neuronal mechanisms; reason why any damage at these levels, favors the 
partial or total loss of erection. These damages are not only structural but also functionally.  
The figure 1 describes the main physiological mechanisms that regulate the erectile function, 
and the morpho-physiological organizations that might suffer damages during DM.  
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Fig. 1. Schematic representation of central and intracavernosal mechanisms involved in the 
control of erection. External visual, gustative, auditory, imaginative and tactile are 
transmitted to the rhinencephalon, the limbic cortex and thalamic nuclei, and are integrated 
into the hypothalamic medial preoptic area (M-POA) where they stimulate supraspinal 
erections (psychogenic erection). Up box: serotonin (5HT), corticotrophin-releasing-hormone 
(CRH) and β-endorphin (βEP) exert inhibitory effects, while gonadotrophin-releasing-
hormone (GnRH), dopamine (DA) and oxytocin (OX) are the main stimulators of 
psychogenic erections. Hypothalamic projections (possibly oxytocinergic) to the spinal cord 
control thoracolumbar sympathetic (T11-L2) and sacral parasympathetic stimulation from 
(S2 to S4) fibers which inhibit and stimulate the erection, respectively. Direct genital stimuli 
initiate a local neural loop leading to parasympathetic stimulation from S2 to S4 and 
reflexogenic erection. Down box: intracavernosal mechanisms of erection involve 
cholinergic, adrenergic, and non-adrenergic non-cholinergic (NANC) nervous fibers. The 
main stimulators of smooth muscle cell contraction (detumescence) are norepinephrine (NE) 
and endothelin-1 (ET1), while acetylcholine (ACH) and nitric oxide (NO) are the main 
mediators of smooth muscle cell relaxation and erection via reduction of intracelular 
calcium (Ca+2) content. Blood oxygen tension (pO2) in the sinusoids inversely regulates 
smooth muscle cell transforming growth factor-β (TGFB) expression and collagen 
accumulation in the pericellular spaces. Modified from Fabbri et al., 1997.  
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4. Animal models of diabetes employed in the study of ED 
In recent years, our understanding of human sexual function and dysfunctions has grown. 
Sexual responses are complex; therefore, different in vivo models exist, focused on the 
neurobiology, psychophysiology and different functional components of male sexual 
responses.  When trying to understand how these preclinical models translate to humans, it 
should also be borne in mind that the primary purpose of sexual activity in animals is 
reproduction, while in humans it is predominantly recreational. The fact that animal sexual 
behaviors are highly stereotyped and species specific, it makes difficult to translate results in 
animal studies to humans (McMurray et al., 2006). 
Erectile function monitoring intracavernosal pressure (ICP) is the most common method to 
preclinical monitoring the quality of an erectile response. ICP has been monitored in both 
conscious and anaesthetised animal models. The development of electronic data capture 
systems now allows various aspects of the ICP response to be measured. The typically 
measured endpoints include basal, peak, and plateau ICP, erection and detumesence time, 
duration of response, area under the ICP time response curve and the number of erections 
observed in a given time period. The aim is to use these end points to quantify the different 
phases and quality of the ICP response and the effect of the actions of drugs upon them 
(McMurray et al., 2006). 
Despite this knowledge, clinical and epidemiological studies seldom separate type-1 
(T1DM) and type-2 (T2DM) DM; however, this section will briefly highlight some of the 
T2DM animal models and animal models of DM induced by chemical treatments (T1DM) 
used to study the ED.  
4.1 Rat models of T2DM 
The obese diabetic Zucker rat (OZR) is a model for T2DM with glucose intolerance and an 
autosomal recessive mutation in the leptin gene. It develops hyperinsulinemia, insulin 
resistance, and hyperlipidemia at an early age with progression to proteinuria and 
glomerular injury (Kasiske et al., 1992). Similar characteristics exist between the OZR and 
patients with T2DM including obesity, hypertension, and impaired vasodilation. The 
BBZ/WOR rat is a cross between the BB/WOR rat a model for autoimmune diabetes and a 
Zucker rat. Obese BBZ/WOR rats develop insulin resistance, and hyperglycemia with 
higher mean serum glucose levels compared with lean T2DM rats (Vernet et al., 1995). 
Otsuka Long-Evans Tokushima Fatty (OLETF) rats develop spontaneous diabetes by 
selective breeding. Male rats exhibit late onset hyperglycemia, hypercholesterolemia, and 
mild obesity. In this model, pancreatic islet cells changes mirror those seen in humans with 
T2DM (Kawano et al., 1992). 
4.2 Mouse models of T2DM 
Recently, mouse models of T2DM have been utilized to study ED. The high-fat diet fed 
mouse model was used as an ED experimental model (Xie et al., 2007). C57BL6 mice were 
fed a high-fat, high-simple carbohydrate, and low-fiber diet for 22 weeks, and developed 
obesity with a mean body weight of 39 g, and developed diabetes with a mean fasting 
serum glucose of 223.6 mg/dL. An additional mouse model of T2DM is the db/db mouse 
(Sharma et al., 2003). The db/db mouse has a mutation in the leptin receptor, and develops 
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spontaneous obesity, hyperglycemia, hyperphagia, hyperinsulinemia, and diabetic 
neuropathy, occurring from 10 days to 8 weeks of age.  
4.3 Rabbit and rat models of T1DM induced by chemical treatment 
The models of Alloxan-induced in rabbit (Chang et al., 2003; Vignozzi et al., 2007) and 
Streptozotocin-induced in rat (Vignozzi et al., 2007) of T1DM have been also used to study 
the ED.  
Other animal models of T2DM and insulin resistance exist but have not been used to date to 
study mechanisms of ED during diabetes (Hidalgo-Tamola & Chitaley, 2009).  
Findings gained from the study of some of these animal models have shed light on 
mechanisms underlying the cause of ED during DM. These factors include impaired 
vasodilatory signaling, cavernosal hypercontractility, and veno-occlusion, among others.  
Although hyperglycemia is a common defining feature both: type-1 and type-2 DM, many 
unique characteristics distinguish these conditions, including insulin and lipid levels, 
obesity status, and inflammatory agent profiles. In the laboratory, the presence of ED has 
been established in animal models of both type-1 and type-2 DM. Impaired cavernosal 
vasodilation has been established in type-1 diabetic rodents. This dysfunction appears to be 
mediated by a severe defect in non-adrenergic-non-cholinergic nerve signaling, as well as 
impairment in penile endothelial function. In contrast, type-2 diabetic animals appear to 
have minimal impairment in parasympathetic-mediated dilatory function, but do have 
evidence of endothelial dysfunction. Type-2 diabetic models also exhibit a significant and 
striking increase in cavernosal contractile sensitivity, and a significant veno-occlusive 
disorder, neither of which is consistently reported in type-1 diabetic animals. With the 
distinct mechanisms underlying the ED phenotype in animal models of type-1 and type-2 
diabetes, tailoring therapeutic treatments for diabetic-ED to the specific mechanisms 
underlying this disease complication may be warranted. Further examination of 
mechanisms underlying ED in DM patients may thus lead to significant changes in the way 
urologists diagnose, code, and treat diabetic-ED (Chitaley, 2009). 
5. Mechanisms proposed to explain the ED in DM 
From a historical perspective, theories pertaining to the pathophysiology of ED have 
changed as time has gone by. In the 1960´s, the prevailing wisdom was that most ED had a 
psychogenic origin, and it was only in the second half of the 20th century, as we have 
gained increasing knowledge of the physiology of normal erectile function, that we have 
begun to understand the importance of vascular, endocrine, cellular and neural mechanisms 
in the development of ED (Eardley, 2002). 
There are several ways of classifying the erectile dysfunction causes, for example as organic, 
psychogenic or mixed organic and psychogenic, with organic erectile dysfunction being the 
most common form (Maas et al., 2002). However, take into account the way in which disease 
can interfere with erection, the classification can be: psychogenic, vascular, neural, cellular, 
endocrine, and iatrogenic (Eardley, 2002). As was showed above by epidemiological studies 
(Feldman et al., 1994; Saigal et al., 2006), the risk of erectile dysfunction increases with 
diabetes and it is in relation with several pathogenic mechanisms in diabetes disease 
involved in precipitating and maintaining the ED. 
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As it is showed in the figure 2, the physiopathology of ED in DM is multifactorial and in the 
following section, we address some of these pathophysiological mechanisms being so far 
taken into account to explain the development of ED in DM. 
 
Fig. 2. Mechanisms of diabetes-associated erectile dysfunction.  
5.1 Endothelial dysfunction 
Several clinical and laboratory studies demonstrate that endothelial dysfunction is an 
important mechanism for the development of ED associated with T2DM. ED is usually 
described as a decrease in the bioavailability of NO, as a result of decreased expression 
and/or activity of eNOS, including increased removal of NO. Damage to the endothelium-
dependent vasoreactivity has been demonstrated in various animal models of T2DM. 
Myograph in vitro studies in mice fed with a high fat diet, db/db diabetic mice and obese 
Zucker rats have shown that the ability of muscle relaxation of the cavernous tissue 
decreases even when stimulated with acetylcholine (Luttrell et al., 2008; Wingard et al., 2007; 
Xie et al., 2007). Jesmin et al., observed a decrease of the immunofluorescent staining of 
eNOS and the expression of this enzyme in the penile tissue of Long-Evans Tokushima 
Otsuka obese rats, with respect to controls (Jesmin et al., 2003). The decrease in eNOS 
mRNA expression suggests that reduced expression of eNOS is initiated at the gene 
transcription level. The alteration in the eNOS activation is another mechanism that 
contributes to decreased bioavailability of NO. eNOS activation occurs through 
phosphorylation of serine-177 residue by serine/threonine protein kinase Akt. In turn, the 
Akt-dependent pathway regulates the phosphorylation of eNOS mediated by the vascular 
endothelial growth factor (VEGF). The effects of VEGF include proliferation, migration, 
angiogenesis, and antiapoptosis in endothelial cells. VEGF increased the phosphorylation 
and expression of antiapoptotic proteins, mediated by eNOS. It is considered that in the ED, 
vascular repair mechanisms mediated by VEGF are damaged, probably because the 
expression of the VEGF and its receptors are altered in the cavernous endothelium, 
conditioning its angiogenic functions (Costa & Vendeira, 2007). In addition to the decreased 
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eNOS activity, the increased removal of NO by free radicals and oxidative agents has been 
shown to be important in the cavernous endothelial dysfunction in diabetes-associated ED 
models (Hidalgo-Tamola & Chitaley, 2009). Endothelins (ET) are potent vasoconstrictor 
peptides that stimulate the contraction of trabecular smooth muscle of the corpus 
cavernosum. No one knows the exact involvement of ET on the pathogenesis of ED. High 
levels of ET-1 observed in diabetic patients could be enough to cause ED, although this does 
not happen. However, the high intracellular calcium concentration resulting from this 
condition modulates gene expression sufficiently to cause the proliferation of smooth 
muscle. Alternatively, alterations in ET receptor sensitivity in conditions such as diabetes 
and hypertension can enhance the processes of vasoconstriction. It is possible that the ET 
system may be relevant in ED, but under certain conditions where there is global 
endothelial dysfunction, such as diabetes and systemic sclerosis, the use of ET antagonists in 
these patients could be beneficial (Ritchie & Sullivan, 2010).  
5.1.1 Failure of the signaling mechanism of vasodilation 
Maintenance of cavernosal vasodilation has been hypothesized to occur through the 
activation of eNOS in endothelial cells, presumably in response to shear stress. Data from 
animal models of T2DM support the findings of impaired vasodilation in T2DM humans. 
Accompanying the impaired vasodilatory response, total penile NOS activity was found to 
be decreased in the BBZ/WOR rat model (Vernet et al., 1995). Similar result was showed by 
an age-matched case controlled study of 30 patients with T2DM and ED, where was found 
impaired the cavernosal vasodilation (De Angelis et al., 2001).  
Vascular disease is probably the most common cause of ED, and of all the vascular causes, 
the commonest is atherosclerosis; however, DM joined with other risk factors, namely 
smoking, hypertension and hyperlipidaemia are also indirectly associated with the 
development of ED (Fig.3). A reduced arterial inflow leads to relative hypoxia within the 
penis with subsequent cellular effects. The crucial cellular mediator appears to be TGF-β1, 
which is increased in hypoxia and induces trophic changes in the cavernosal smooth muscle, 
and failure of the venous-occlusive mechanism (Feldman et al., 1994; Johannes et al., 2000).   
 
Fig. 3. Schematic representation of the relationship between the DM and other risks factors, 
with the development of vascular damages that favor the ED in the diabetic patient. 
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On the other hand, DM can injure cells and cause ED in a direct way. Diabetes damage the 
endothelium impairs the vascular response of the penis to neural stimuli. The structural 
changes in the endothelium that are produced by diabetes are accompanied by functional 
changes that result in impaired smooth muscle relaxation (Cartledge et al., 2001a; Saenz de 
Tejada et al., 1989). In the figure 4, it is possible observe the alteration of penile vascular 
endothelium of the rabbit with DM.  
 
Fig. 4. Electron micrographs of normal penile vascular endothelium (a) and the effect of 
diabetes in the rabbit (b). Note the ragged appearance of the endothelium and the 
deposition of red (rb) and white (wb) blood cells in diabetes. (Micrographs published by the 
Dr. Ian Eardley in Pathophysiology of erectile dysfunction. (2002). British Journal of Diabetes 
and Vascular Disease, Vol. 2, No. 4, pp. 272-6, ISSN 1474-6514, by courtesy of Sullivan, M. 
5.1.2 Venous-occlusive dysfunction 
In ED, venous-occlusive dysfunction or venous leakage, involves the premature escape of 
blood inside the corpuses cavernous by incompetence of their drainage system and 
subsequent inability to reach the intracavernous pressure necessary to provide an effective 
stiffness. By Doppler studies and Pharmacocavernosometry, it has been observed that a high 
percentage of patients with T2DM present venous leak (Colakoglu et al., 1999; Metro & 
Broderick, 1999). Evidence from animal studies has demonstrated the importance of venous-
occlusive dysfunction in the development of ED in T2DM. It is considered that the alteration 
in the process of veno-occlusion may be caused by changes in the structure of the penis, the 
cells and/or the content of the extracellular matrix. In this regard, the expression of VEGF 
has broad implications in the structure of the penis, resulting in changes in the rate of 
apoptosis. The decrease in VEGF expression correlates with elevated levels of pro-apoptotic 
proteins such as Bcl-2, so it is suggested that the decrease of VEGF in penile tissue in T2DM 
increases apoptosis and loss of erectile cells. In other studies with animal models of T2DM, 
there has been observed an alteration in the expression of collagen and the rate of smooth 
muscle/collagen in cavernous tissue. Likewise, decreased elastin has been found in the 
corpus cavernosum, specifically, decreased expression of tropoelastin mRNA, precursor 
protein of elastin and fibrillin-1. Structural alterations in the tunica albuginea caused by 
T2DM, could affect the compliance of the corpus cavernosum, required for veno-occlusion 
and intracavernous pressure maintenance (Hidalgo-Tamola & Chitaley, 2009). 
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5.1.3 Diabetic micro and macro angiopathy 
Clinical and biochemical evidence support the participation of the microangiopathic 
complications of diabetes in the pathogenesis of ED. Multiple studies have shown that 
chronic hyperglycemia (which is the main determinant of the microangiopathic 
complications) is a strong risk factor for ED. Diabetes duration and other microvascular 
complications (i.e. retinopathy, neuropathy and nephropathy) are predictors of the 
occurrence of ED (Bhasin et al., 2007). 
Somatic and autonomic nerve dysfunction is present in a large percentage of individuals 
with diabetes-associated ED (Chitaley et al., 2009). Its presence is demonstrated by the 
existence of both, longer latencies in the evoked potentials of pudendal nerves and 
abnormal bulbar urethral and urethroanal reflexes. Diabetes causes degeneration of the 
nitrergic nerves, which participates in the nitric oxide-dependent cavernosal smooth muscle 
relaxation. A central neuropathic mechanism has been postulated by several authors 
(Costabile, 2003). 
Some of the biochemical mechanisms that induce endothelial dysfunction and decreased 
generation of nitric oxide participate also in the pathogenesis of diabetic neuropathy (Gur et 
al., 2009). An example is the oxidative stress. Superoxide radicals are present in high amount 
in cavernosal tissues.  Superoxide anion reacts with nitric oxide to form peroxynitrite 
resulting in decreased nitric oxide bioavailability (Boulton et al., 2004). In addition 
peroxynitrite is a highly toxic compound for vascular cells and neurons. It causes 
mitochondrial dysfunction, oxidative DNA damage and apoptosis. Other examples are the 
activation of protein kinase C and the presence of advance glycation end-products (AGEs). 
1,2-Diacylglycerol (DAG), a metabolite responsible of lipotoxicity in obesity and T2DM, 
activates protein kinase C (in particular the  isoform (PKC-). These enzymes participate in 
multiple biological networks. This enzyme is activated also by free radicals.  Experimental 
data suggest that activated PKC- plays a major role in the hyperglycemia-related tissular 
damage; one of the possible explanations is the induction of the nuclear kappa B pathway.  
It is also involved in the carvernosal corpus smooth muscle contraction. On the other hand, 
chronic hyperglycemia causes the formation of AGEs which induces tissue damage by 
modifying molecules, activating inflammation and stimulating the synthesis of growth 
factors. AGEs modify cytoskeletal and myelin structure (England & Asbury, 2004). These 
changes correlate with a reduction in myelinated fiber density in peripheral nerves. Also, 
AGEs quench endothelium derived nitric oxide. As result, AGEs decreases smooth muscle 
relaxation and impairs erectile function (Thorve et al., 2011). 
The macrovascular complications during the DM contribute to the development of ED (Chai 
et al., 2009).  Vascular atherosclerotic disease of penile arteries is present in 70-80% of cases 
with ED. Occlusion of the cavernosal arteries could be a contributing factor in the long term. 
However, recent studies have shown that structural arterial changes in the penile vascular 
bed could exist even in cases with ED free of coronary heart disease.  
5.2 Diabetic neuropathy 
Neuropathy is a common complication of diabetes, in which there is nerve damage as a 
result of hyperglycemia. The damage involves both somatic and autonomic nerves. 
Autonomic nerves of the parasympathetic division stimulate relaxation of the muscles in the 
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penis; with the resulting erection, those of the sympathetic division are responsible for the 
contraction of muscles in the penis and thus maintain penile flaccidity. Although the 
mechanisms by which it occurs are not completely clear, it is known that nerve fibers are 
structurally modified by the effect of substances derived from the metabolism of excess 
glucose, which determines the loss of myelin. The loss of myelin promotes delayed nerve 
transmission, both reception of motor commands and other. Likewise, it is considered that 
the damage is caused in turn by the injury of blood vessels supplying the nerves. 
Neuropathy is another important mechanism responsible for diabetes-associated ED 
(Costabile, 2003). Diabetes is notorious for its microvascular complications, particularly 
autonomic neuropathy and peripheral neuropathy (Agarwal et al., 2003). It has been noted 
that patients with diabetic and neuropathic ED have similar frequencies of somatic and 
autonomic nervous system neuropathies, suggesting that neuropathy contributes 
significantly to the diabetes-associated ED. A recent study showed the connection between 
diabetic and neuropathic ED, demonstrating the presence of apoptotic pathways in the 
cavernous nerves in both disease processes (Mc Vary et al., 2006). The underlying cause of 
ED, which is the result of diabetic neuropathy, might be linked to selective nitrergic 
degeneration, which has been observed in the diabetic rat penis. This selective 
neurodegeneration seems to result in decreased nNOS activity and decreased NO 
production, which leads to damage nitrergic relaxation of corpus cavernosum in diabetic 
patients (Cellek et al., 1999). Additionally, NO could participate in the selective nitrergic 
degeneration through the formation of oxygen free radicals. It has been suggested that 
oxidative damage secondary to the production of peroxynitrite derived from NO may 
contribute to neurodegeneration (Cartledge et al., 2001a; Cellek et al., 1999). Several studies 
have shown that inhibition of NO synthase and NO production; prevent nitrergic 
degeneration, suggesting that this is a NO dependent process (Cellek et al., 1999). 
5.2.1 Failure of the mechanism of nitric oxide synthesis in the nervous system non-
adrenergic non-cholinergic 
DM is one of the major risk factors to develop ED. Hyperglycemia is considered the cause of 
many vascular complications and metabolic alterations associated with both T1DM and 
T2DM. Diabetes-associated ED has been attributed to a reduction in the number of NOS-
containing nerves, the impairment of NOS activity, and both neurogenic- and endothelium-
mediated smooth muscle relaxation, and also to downregulation of the mediators 
downstream from NO, such as cGMP and PKG-1, in the corpus cavernosum (Musicki & 
Burnett, 2006).  
In the cell, NO synthases have to compete, with other enzymes with activity of arginases, for 
the substrate L-arginine. Inhibition of arginase activity by 2(S)-amino-6-boronohexonic acid 
(ABH) has been shown to cause significant enhancement of non-adrenergic, non-cholinergic 
nerve-mediated relaxation of penile corpus cavernosum smooth muscle, suggesting that 
arginase inhibition sustains L-arginine concentrations for be used in the NO synthesis (Cox 
et al., 1999). Moreover, another study demonstrated that diabetic corpus cavernosum from 
humans with ED had higher levels of arginase II protein, gene expression and enzyme 
activity than normal human cavernosal tissue. The impaired ability of diabetic tissue to 
synthesize NO was reversed by the selective inhibition of arginase activity by ABH. 
Increased expression of arginase II in diabetic cavernosal tissue may therefore contribute to 
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the diabetes-associated ED (Bivalacqua et al., 2001). Another explanation for decreased 
eNOS activity in the diabetic penis can be due to a reduced penile L-arginine content. Oral 
administration of L-arginine to diabetic rabbits increases endothelium-dependent relaxation 
of cavernosal tissue by improving the NO biosynthesis (Yildirim et al., 1999). 
5.3 Oxidative stress 
Oxidative stress occurs when there is an imbalance between pro-oxidants and the ability of 
the antioxidants to scavenge excess reactive oxygen species. However, its role in ED has not 
been investigated comprehensively but, significant associations between the production of 
reactive oxygen species and ED have been showed, especially in diabetic animal models. 
NO is a highly reactive free radical that undergoes nonenzymatic reaction with 
oxyhemoglobin or that reacts with free radicals, such as superoxide anion, to form 
peroxynitrite (Beckman & Koppenol, 1996). This observation first highlighted the 
importance of oxidative stress in ED. 
Reactive oxygen species (ROS) are formed during regular metabolism due to the univalent 
reduction of oxygen molecule. Superoxide (O2-) is the most important among the ROS. 
Hydrogen peroxide (H2O2), hypochlorous acid (HOCL), and peroxynitrite (OONO-) are 
other important free radicals implicated in the pathophysiological mechanism of vascular 
disease. The vascular endothelium is the major source for these free radicals (Beckman & 
Koppenol, 1996). Superoxide dismutase (SOD) is an important enzyme that removes the 
superoxide radicals from the human body. There are 3 types of SOD isoenzymes: cytosolic, 
mitochondrial, and extracellular. Extracellular SOD reportedly plays a critical role in 
maintaining the redox state of vascular interstitium and thereby prevents the 
pathophysiological effects of superoxide in the vasculature. 
The interaction between NO and reactive oxygen species (ROS) is one of the important 
mechanisms implicated in the pathophysiological process of ED. NO interacts with 
superoxide to form peroxynitrite, which has been reported to play a central role in 
atherogenesis. Peroxynitrite reacts with the tyrosyl residue of proteins, which inactivates 
superoxide dismutase and leads to decreased removal of superoxide. This further increases 
the formation of peroxynitrite and reduces the available NO concentration. Peroxynitrite 
causes smooth-muscle relaxation but is less potent than NO. Also, peroxynitrite and 
superoxide have been reported to increase the incidence of apoptosis in the endothelium. 
This leads to denudation of endothelium and further reduction of available NO (Agarwal et 
al., 2006). On the other hands a reduced NO concentration aggravates the adhesion of 
platelets to the endothelium, and the co-adhesion of neutrophils to platelets as well as the 
endothelium through the expression of adhesion molecules, releasing large amounts of 
superoxide which reduces more the available NO by the formation of peroxynitrite, 
countering erectile drive as well as promoting further more adhesion of platelets and 
neutrophils. Under this condition, is favored the releasing of substances (thromboxane A2 
and serotonin) that cause vasoconstriction (Jeremy et al., 2000), taking place a vicious circle 
that generates the vasculopathic erectile dysfunction.  
Another mechanism has been implicated in diabetes-associated ED is the activation of 
protein kinase C, this is an enzyme that modulates several cellular events, and increased 
levels of this enzyme are associated with increased production of ROS and reduced levels of 
NO, which can be prevented by administration of antioxidants (Ganz & Seftel, 2000). 
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The studies demonstrate that oxidative stress has a vital role in the development of diabetes-
associated ED. Hyperglycemia is an important mediator of increased production of ROS 
leading to impaired endothelial function and structural impairment in the diabetic corpus 
cavernosum. The corpus cavernosum of diabetic rats and diabetic men with ED exhibits 
increased lipid peroxidation, upregulation of superoxide anion, and decreased antioxidants 
levels, suggestive of oxidative stress (Bivalacqua et al., 2005).  
5.4 Involvement of advanced glycation end-products 
The proposed mechanisms for ED in DM patients include: damage in the synthesis of NO, 
reduction  in the activity of PKG-1, increased endothelin and endothelin B (ETB) receptor 
binding sites; ultrastructural changes in the endothelium, upregulation of the RhoA/Rho-
kinase pathway, neuropathy, increased levels of oxygen free radicals and elevated 
concentration of advanced glycation end-products (AGEs) (Jiaan et al., 1995; Moore & 
Wang, 2006; Sullivan et al., 1997; Thorve et al., 2011). 
Hyperglycemia in DM leads to AGEs, which are derived from non-enzymatic glycosylation 
reactions, actually known as glycation. Glucose reacts with amino groups, producing what 
is known as a Schiff base. Schiff base is modified to form more stable Amadori products. 
Some of these Amadori products undergo irreversible chemical changes and become AGEs 
(Brownlee et al., 1988; Cárdenas-León et al., 2009; Cartledge et al., 2001b) (Fig. 5). The action 
of AGEs is mostly via cell surface receptors, such as the receptor for AGEs (RAGE), 
P60/OST48 protein (R-1), 80KH phosphoprotein (R-2) and galectin-3 (R-3), scavenger 
receptor II, lactoferrin-like polypeptide, and CD-36 (Basta et al., 2004).  Some of the receptors 
are likely to contribute to clearance of AGEs, whereas others may mediate many of the 
adverse effects, such as quenching of NO, impairment of extracellular matrix and tissue 
remodeling, modification of circulating proteins, and receptor-mediated production of ROS. 
AGEs can also form covalent bonds with collagen vascular, leading to thickening of blood 
vessels, decreased elasticity, endothelial dysfunction and atherosclerosis (Bucala et al., 1991; 
Singh et al., 2001). AGEs are accumulated during aging (Jiaan et al., 1995) and diabetes. They 
are formed abundantly when glucose remains high for prolonged periods (Bucala et al., 
1991; Seftel et al., 1997). AGEs have been found elevated in the corpus cavernosum and tunica 
albuginea of the penis of diabetics rats and humans (Cartledge et al., 2001b; Cirino et al., 2006; 
Jiaan et al., 1995; Seftel et al., 1997). It is thought that AGEs may contribute to diabetes-
associated ED, generating oxygen free radicals, which induce cell damage by oxidative 
processes and also remove NO, culminating with the decrease of cGMP and affecting the 
cavernous smooth muscle relaxation (Bivalacqua et al., 2005; Cartledge et al., 2001b). AGEs 
may take effect at the molecular level on different channels and receptors in cavernous smooth 
muscle cells, particularly on potassium channels, which facilitate the release of intracellular 
calcium and subsequent cavernous smooth muscle relaxation. Damage to the potassium 
channels could lead to lost of the relaxation capacity of the cavernous smooth muscle and to 
early onset of diabetes-associated ED (Cartledge et al., 2001b; Costabile, 2003). Also, AGEs are 
considered to be related to ED during diabetes by increasing the expression of mediators of 
vascular damage such as VEGF and ET-1, which have mitogenic and vasoconstrictor activities 
(Morano, 2003). Several studies have shown damage to smooth muscle relaxation in the corpus 
cavernosum and penile ED in diabetic rat in the presence of AGEs (Cartledge et al., 2001b; 
Usta et al., 2003). Also, it has been observed that under conditions of diabetes, the combined 
effect of AGEs and their receptor (RAGE), may increase the activity of ET-1 in the cavernous 
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tissue and thus promote the development of diabetes-associated ED (Chen et al., 2008). The 
involvement of AGEs in diabetes-associated ED has been demonstrated by using 
aminoguanidine, an inhibitor of AGEs formation (Usta et al., 2004) and ALT-711, a compound 
that breaks down formed AGEs (Usta et al., 2006), and observing improvement in 
endothelium-dependent cavernosal smooth muscle relaxation in vitro (Cellek et al., 2004) and 
erectile responses in vivo (Usta et al., 2003).  
 
Fig. 5. Schematic representation: mechanisms of main Advanced Glycation End-products 
(AGEs) formation. CML: Carboxymethyl lysine; CEL: Carboxyethyl lysine.  
5.5 Hyper-contractility of the cavernous body 
ED is more common in diabetic patients. Hyperglycemia among others, leads to an altered 
vasodilator neural impulse, causing smooth muscle hyperkinesis and altered veno-occlusion 
process (Hidalgo-Tamola & Chitaley, 2009). Hypercontractility of corpus cavernosum may 
occur as a result of heightened sympathetic nervous system activity and/or increase in 
signaling to smooth muscle. The role of hyperkinesis of smooth muscle cells during T2DM-
associated ED is difficult to discern from clinical studies, since most of them combine 
patients with T1DM and T2DM in the same group of evaluation. However, several animal 
studies suggest the importance of hyperkinesis in T2DM-associated ED.  
Hyperinsulinemia and insulin resistance are associated with overactive sympathetic 
nervous system, which increases smooth muscle tone and keeps the penis in flaccid state. 
Currently it is unclear whether the increase in contractility is only due to sympathetic 
overactivity or the gloom of the signaling pathways in smooth muscle play a predominant 
role (Carneiro, 2008). The results obtained by using diabetic obese Zucker rats as an 
experimental model, suggest that increased smooth muscle tone is mediated by protein 
kinase C and RhoA/Rho-kinase pathway (Wingard et al., 2007). During normal erection, 
this pathway is inhibited by NO (Mills, 2002), but during diabetes the RhoA/Rho-kinase 
pathway activity is elevated and suppresses eNOS gene expression and enzyme activity in 
the penis (Bivalacqua et al., 2004). It has been reported that corpus cavernosal tissue, 
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obtained from alloxan-induced diabetic rabbits, exhibits increased RhoA and Rho-kinase ß 
expression (Chang et al., 2003). It is considered that other modulators of tone of smooth 
muscle cells might be involved in T2DM-associated ED. In addition to the altered 
vasodilator stimuli and increased contractility of the corpus cavernosum, which limit the 
flow of blood into the penis, the inability to limit the outflow of blood due to a disorder of 
veno-occlusion, may also be a factor in T2DM-associated ED. ED during diabetes is 
associated among others with decreased PKG-1. In smooth muscle a major target of the 
PKG-1 are the calcium-sensitive potassium channels (BKCa), the overactivation of which 
hyperpolarizes smooth muscle cells, causing relaxation. But during diabetes the activity of 
PKG-1 and therefore the activity of the BKCa are low and the relaxation mechanism is 
affected. It has been observed that the elimination of BKCa channels in an experimental 
model causes hypercontractility of the smooth muscle and ED (Werner et al., 2008). 
5.5.1 Relationship between glycaemia, dyslipidemia, hypertension and its medical 
treatment with ED in DM patients 
The hyperglycemia and dyslipidemia associated to DM favors the mechanisms of oxidative 
stress, endothelial damage and the development of atherosclerosis (Li, et al., 2011; Kumar, et 
al., 2010) leading to hypertension as consequence of endothelial dysfunction and loss of 
vascular relaxation.  Due to these considerations, it is extremely important the metabolic 
control of DM subjects to avoid the appearance of ED. 
Weight loss is the prime objective of therapy. Several studies in which intensive lifestyle 
programs or bariatric surgery were implemented to lose weight have shown that erectile 
function improves in direct proportion with the difference in body weight. The potential 
mechanisms include improved endothelial function and nitric oxide bioavailability, 
decreased inflammation, increased testosterone plasma levels, and improved mood and self-
esteem. In addition, weight loss is the cornerstone for the treatment of hyperglycemia, 
hypertriglyceridemia, arterial hypertension and hypoalphalipoproteinemia (Khatana et al., 
2008). Patients should be encouraged to quit smoking, to reduce their alcohol intake and to 
give up recreational drugs. Prescription drugs and over the-counter medications should be 
checked for possible contributors to ED. Relationship counseling and a psychiatric 
medication is useful to treat anxiety and depression. 
An association exists between glycemic control and ED in men with diabetes. Hermans et 
al., analyzed 221 consecutive male outpatients with T2DM in whom ED was assessed using 
the International Index of Erectile Function (IIEF-5) questionnaire (Hermans et al., 2009). 
Patients with ED (n=83) were compared with an age-matched controls (n=51).  Patients with 
poor control have increased risk for ED compared to patients with good control. Body 
weight and adiposity are significantly associated with ED. Obesity is associated with an 
odds ratio of 1.5 to 3 for having ED. Other measures of adiposity, including the waist-to-hip 
ratio and abdominal circumference, are also independently associated with ED. A sedentary 
life style increases the risk, independently of its effect on body mass index. Arterial 
hypertension and abnormal plasma lipid level, common co-morbidities of T2DM, are 
associated with ED. Both are linked with endothelial dysfunction, reduced nitric oxide 
synthesis and increased free radicals synthesis. 
Several authors have proposed that treatment of hyperglycemia and cardiovascular risk 
factors should be part of the treatment of ED. Although this proposal is clinically sound, no 
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major randomized controlled studies are available to support it. Only the EDIC trial 
(Epidemiology of Diabetes Intervention and Complications study) have partially evaluated it. 
The EDIC study is an extension of the DDCT trial, a landmark study that demonstrated that 
the correction of hyperglycemia reduces the incidence of microvascular complications. A 
substudy of the EDIC trial (Uro-EDIC) was designed to evaluate the impact of the correction of 
hyperglycemia on the incidence of urologic complications. ED was assessed using the IEFF 
questionnaire. The effect of treatment was evaluated separately in cases (n=280) with or 
without (n=291) microvascular complications. No difference was observed in the incidence of 
ED between men randomized to intensive vs. conventional therapy (OR 1.24, 95% CI 0.68- 
2.28) in cases free of microvascular complications at the beginning of the study. In contrast, 
intensive therapy resulted in a smaller incidence of ED among men with microvascular 
complications (OR 0.33, 95% CI 0.18-0.60).  Regrettably, ED was not included among the study 
outcomes of the main trials that have evaluated the effect of intensive treatment of 
hyperglycemia (i.e. ACCORD trial) in men with T2DM. Future studies including validated ED 
measurements, adequate sample size and important potential confounders are needed to 
measure the benefit of intensive glycemic control in men with poorly controlled diabetes. 
5.6 Androgen loss systemic effects 
The erectile response in mammals is regulated by androgens; in particular it has been 
confirmed that testosterone is an important regulator of the erectile function (Yassin & Saad, 
2008). Is known that 6-12% of men between 40 and 69 years old suffer from hypogonadism. 
In adult men the disease is manifested by erectile dysfunction, among others. Male 
hypogonadism, which is also called testosterone deficiency syndrome, is characterized by 
failure of testicular testosterone production and is especially common in men with T2DM, 
affecting one third of them. Testosterone acts on the penile tissues involved in the 
mechanism of erection, so deficiency of this hormone, impairs erectile capacity. The 
pathophysiological mechanisms of low circulating testosterone concentrations are unknown, 
but it has been suggested that obesity associated with T2DM, helps to reduce testosterone 
levels by increasing the conversion of testosterone to estradiol in adipose tissue. The 
increase in the concentration of estradiol leads in turn to a suppression of hipothalamic 
gonadotrophin releasing hormone (GnRH), which is evidenced by a reduced secretion of 
pituitary gonadrotropins (luteinizing hormone, LH and follicle stimulating hormone, FSH), 
which reduces in turn the secretion of testosterone by the Leydig cells and spermatogenesis 
in the seminiferous tubules, thus manifesting as hypogonadism. This may explain the 
inverse relationship between BMI and plasma concentrations of testosterone (Dhindsa et al., 
2004; Grossmann et al., 2008; Kapoor et al., 2007; Rhoden et al., 2005; Traish et al., 2009). 
Male hypogonadism is associated with increased adipose tissue. In men with more than 
160% of ideal body weight, concentrations of plasma testosterone and sex hormone-binding 
globulin (SHBG) are usually low while estrogen levels, from the conversion of adrenal 
androgens in adipose tissue, increase. In men with morbid obesity weighing more than 
200% over the ideal weight, free testosterone may decrease. The concentrations of free 
testosterone and SHBG show an inverse relationship with waist circumference (WC) (Osuna 
et al., 2006; Pasquali et al., 1997; Svartberg, 2007). With the increase in adipose tissue also 
increases the production of leptin; favors the insulin resistance and therefore the appearance 
of hyperinsulinemia. Under these conditions, both leptin and insulin act on Leydig cells and 
inhibit testosterone synthesis (Pitteloud et al., 2005; Soderberg et al., 2001) (Fig. 6). 
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Fig. 6. Relationship between obesity, androgen deficiency (hypogonadism), metabolic 
syndrome and ED. The increase in adipose tissue and its accumulation in abdominal region, 
increases the production of adipokines and free fatty acids, this in turn, generates insulin 
resistance and hyperinsulinemia. The excess of insulin reduces the hepatic synthesis of 
SHBG and IGFBP-1 with the consequent increase of free IGF-1. The high concentrations of 
IGF-I and insulin act synergically on the testis and the adrenals glands, reducing the 
androgens secretion. In the testis, moreover, because of the limited effect that the reduced 
LH concentration exerts on the synthesis of testosterone, the effect is more marked. 
Probably, the increase in aromatization of androgens by adipose tissue, contributes to the 
hypoandrogenemia, together with the low levels of FSH which limit the spermatic 
development, lead to ED and the hypogonadotropic hypogonadism condition, which is an 
infertility factor. 
Androgen deficiency contributes to pathologies associated with the metabolic syndrome, 
such as obesity, T2DM, hypertension and hyperlipidemia, which affect the endothelium, 
resulting in multiple vascular diseases, including ED, representing the latter, an infertility 
factor (Akishita et al., 2007; Traish et al., 2009; Tripathy et al., 2003) (Fig. 6). Also, several 
studies have shown that low testosterone levels predict development of T2DM in men 
(Tomar et al., 2006). There is evidence that the treatment with testosterone to DM animal 
models improves erectile function by influencing the NO/cGMP/PDE5 pathway (Vignozzi 
et al., 2005). Testosterone supplementation to diabetic animals also down regulates 
RhoA/Rho-kinase signaling (Vignozzi et al., 2007) improving also erectile function. The use 
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of PDE 5 inhibitors like Sildenafil (Viagra), Tadalafil (Cialis) and Vardenafil (Levitra) for ED 
treatment has allowed a better management of this condition (Yassin & Saad, 2008). In 
particular, combined therapy of testosterone and sildenafil, improves erectile function in 
patients with T2DM (Hidalgo-Tamola & Chitaley, 2009). 
5.7 Other causes of ED in diabetes 
5.7.1 Viral and Bacterial pathogens 
A role for viral and bacterial pathogens in the development of atherosclerosis has been 
suggested by multiple studies. Most evidence for this infection theory comes from 
seroepidemiological and experimental studies with cytomegalovirus (CMV) and Chlamydia 
pneumonia (CP), which are intracellular pathogens and can directly infect vascular wall cells, 
including endothelial cells and smooth muscle cells. Although still under debate, there appears 
to be an association of CMV and CP with the presence or development of atherosclerotic 
vascular disease in diabetes. Direct infection of endothelial cells leads to pro-coagulant activity 
and a local vascular pro-inflammatory response. Although the exact pathogenesis of ED in 
men with DM is still unclear, endothelial dysfunction plays a pivotal role and some studies 
suggested an association between ED and CMV and/or CP seropositivity in men with 
diabetes. Also, levels of the inflammatory markers as C-reactive protein and fibrinogen were 
elevated in patients with diabetes-associated ED (Blans et al., 2006).  
5.7.2 Drugs used in the diabetic patient 
A large number of drugs used in the managing of the DM patients may impair sexual 
function, either by an effect upon erectile and ejaculatory function or sex drive. Some of 
them are used as part of the diabetes treatment or others associated conditions like 
hypertension, anxiety and depression. The use of these drugs very rarely produces ED by 
themselves. Side effects usually appear adjunct to another pathophysiological mechanism 
(Eardley, 2002; Elías-Calles & Licea, 2003) (Table 1). 
 
Type of drug: Secondary sexual effect: 
  
Antihypertensive (Diuretics):  
Spironolactone Diminution of the libido, ED 
Thiazide Diminution of the libido, ED 
  
Agents of central action:  
Methyldopa                                                           Diminution of the libido, ED 
Clonidine                                                                ED 
Reserpine Diminution of the libido, ED and depression 
  
Alpha-adrenergic blocking agents:  
Prazosin Retrograde ejaculation 
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Type of drug: Secondary sexual effect: 
Terazosin Retrograde ejaculation 
  
Beta-adrenergic blocking agents:  
Propranolol Diminution of the libido, ED 
Metoprolol Diminution of the libido, ED 
  
Alpha and Beta Blocking Agents:  
Labetalol Inhibition of the ejaculation 
  
Blocking of the sympathetic ganglia:  
Guanethidine ED, Retrograde ejaculation 
  
Inhibitor of the angiotensin-converting 
enzyme: 
 
Lisinopril ED in 1% of the cases 
  
Psychiatric drugs (Tricyclic Antidepressants):   
Amitriptyline ED, Inhibition of the ejaculation 
Amoxapine Diminution of the libido, ED 
Desipramine Inhibition of the ejaculation 
Imipramine Inhibition of the ejaculation 
Maprotiline Inhibition of the ejaculation 
Nortriptyline Inhibition of the ejaculation 
Protriptyline ED, Inhibition of the ejaculation 
  
Atypical agent:  
Trazodone Priapism 
  
Inhibitors of Monoamine oxidase:  
Isocarboxazid Inhibition of the ejaculation 
Phenelzine ED, Inhibition of the ejaculation 
  
Antipsychotic:  
Thioridazine Diminution of the libido, Inhibition of the ejaculation 
Chlorpromazine Inhibition of the ejaculation 
Mesoridazine Diminution of the libido, Inhibition of the ejaculation 
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Type of drug: Secondary sexual effect: 
Fluphenazine Diminution of the libido, Inhibition of the ejaculation 
  
Serotonin reuptake inhibitor:  
Fluoxetine Anorgasmia 
Trifluoperazine Inhibition of the ejaculation 
Chlorprothixene Inhibition of the ejaculation 
Haloperidol  Inhibition of the ejaculation 
  
Anti-mania:  
Lithium carbonate Possible ED 
  
Anti-ulcer:  
Cimetidine Diminution of the libido, ED, Gynecomastia 
Table 1. Drugs used in the managing of the metabolic and psychological state of the diabetic 
patients with potential capacity to induce sexual dysfunctions including ED. 
6. Conclusions 
DM is one of the more important risk factors to the development ED. The uncontrolled 
metabolic state (characterized by hyperglycaemia, dyslipidemia, insulin resistance, 
hyperinsulinemia) induce oxidative stress, failure in the signaling mechanism of 
vasodilation, venous-occlusive dysfunction, atherosclerosis, angiopathy, neuropathy, 
alterations of the NO-mediated pathways, the formation of advanced glycation end-
products, hypercontractility of the cavernous body, overweight and androgen loss systemic 
effects, and ED as consequence. 
Although hyperglycemia is a common defining feature in type-1 and type-2 DM, many 
unique characteristics distinguish these diseases, including insulin and lipid levels, obesity 
status, and inflammatory agent profiles. Impaired cavernosal vasodilation has been 
established in T1DM rodents. This dysfunction appears to be mediated by a severe defect in 
non-adrenergic-non-cholinergic nerve signaling, as well as impairment in penile endothelial 
function. In contrast, T2DM animals appear to have minimal impairment in 
parasympathetic-mediated dilatory function, but do have evidence of endothelial 
dysfunction. T2DM models also exhibit a significant and striking increase in cavernosal 
contractile sensitivity, and a significant veno-occlusive disorder, neither of which is 
consistently reported in T1DM animals. With the distinct mechanisms underlying the ED 
phenotype in animal models of type-1 and type-2 DM, the therapeutic treatments for 
diabetes-associated ED most be adjustment to the specific mechanisms underlying this 
disease complication. Further examination of mechanisms underlying ED in DM patients 
may thus lead to significant changes in the way urologists diagnose, code, and treat 
diabetes-associated ED. An adequate metabolic and psychological control is the more 
effective way to avoid the ED in DM; for these reasons it is of extreme importance the 
opportune and specialized medical intervention and support. 
www.intechopen.com
 Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus 
 
89 
7. References 
[1] Agarwal, S.K., Prakash, A., & Singh, N.P. (2003). Erectile dysfunction in diabetes 
mellitus: Novel treatments. International Journal of Diabetes in Developing Countries, 
Vol. 23, pp. 94-8, ISSN 0973-3930.  
[2] Agarwal, A., Nandipati, K.C., Sharma, R.K., Zippe, C.D., & Raina, R. (2006). Role of 
oxidative stress in the pathophysiological mechanism of erectile dysfunction. 
Journal of Andrology, Vol. 27, No. 3, pp. 335-47, ISSN 0196-3635. 
[3] Akishita, M., Hashimoto, M., Ohike, Y., Ogawa, S., Iijima, K., Eto, M., & Ouchi, Y. (2007). 
Low testosterone level is an independent determinant of endothelial dysfunction in 
men. Hypertension Research, Vol. 30, No. 11, pp. 1029-34, ISSN 0916-9636. 
[4] Basta, G., Schmidt, A.M., & De Caterina, R. (2004). Advanced glycation end products 
and vascular inflammation: implications for accelerated atherosclerosis in diabetes. 
Cardiovascular Research, Vol. 63, No. 4, pp. 582-92, ISSN 0008-6363. 
[5] Beckman, J.S. & Koppenol, W.H. (1996). Nitric oxide, superoxide, and peroxynitrite: the 
good, the bad, and ugly. The American journal of physiology, Vol. 271, No. 5 Pt 1, pp. 
C1424-37, ISSN 0002-9513. 
[6] Benet, A.E., & Melman, A. (1995). The epidemiology of erectile dysfunction. Urologic 
Clinics of North America, Vol. 22, No. 4, pp. 699-709, ISSN 0094-0143. 
[7] Bhasin, S., Enzlin, P., Coviello, A., & Basson, R. (2007). Sexual dysfunction in men and 
women with endocrine disorders. The Lancet, Vol. 369, No. 9561, pp. 597-611, ISSN 
0140-6736.  
[8] Bivalacqua, T.J., Champion, H.C., Usta, M.F., Cellek, S., Chitaley, K., Webb, R.C., Lewis, 
R.L., Mills, T.M., Hellstrom, W.J., & Kadowitz, P.J. (2004). RhoA/Rho-kinase 
suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-
associated erectile dysfunction. Proceedings of the National Academy of Sciences of the 
United States of America, Vol. 101, No. 24, pp. 9121-6, ISSN 0027-8424. 
[9] Bivalacqua, T.J., Hellstrom, W.J., Kadowitz, P.J., & Champion, H.C. (2001). Increased 
expression of arginase II in human diabetic corpus cavernosum: in diabetic-
associated erectile dysfunction. Biochemical and Biophysical Research Communications, 
Vol. 283, No. 4, pp. 923-7, ISSN 0006-291X. 
[10] Bivalacqua, T.J., Usta, M.F., Kendirci, M., Pradhan, L., Alvarez, X., Champion, H.C., 
Kadowitz, P.J., & Hellstrom, W.J. (2005). Superoxide anion production in the rat 
penis impairs erectile function in diabetes: influence of in vivo extracellular 
superoxide dismutase gene therapy. The Journal of Sexual Medicine, Vol. 2, No. 2, pp. 
187-97; discussion 197-8, ISSN 1743-6095. 
[11] Blans, M.C., Visseren, F.L., Banga, J.D., Hoekstra, J.B., van der Graaf, Y., Diepersloot, 
R.J., & Bouter, K.P. (2006). Infection induced inflammation is associated with 
erectile dysfunction in men with diabetes. European Journal of Clinical Investigation, 
Vol. 36, No. 7, pp. 497-502, ISSN 0014-2972. 
[12] Bloomgarden, ZT. (1998). American Diabetes Association Annual Meeting. Endothelial 
dysfunction, neuropathy and the diabetic foot, diabetic mastopathy, and erectile 
dysfunction. Diabetes Care, Vol. 21, No. 1, pp. 183-9, ISSN 0149-5992.  
[13] Bortolotti, A., Fedele, D., Chatenoud, L., Colli, E., Coscelli, C., Landoni, M., Lavezzari, 
M., Santeusanio, F., & Parazzini, F. (2001). Cigarette smoking: a risk factor for 
erectile dysfunction in diabetics. European Urology, Vol. 40, No. 4, pp. 392-6; 
discussion 397, ISSN 0302-2838. 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
90
[14] Boulton, A.J., Malik, R.A., Arezzo, J.C., & Sosenko, J.M. (2004). Diabetic somatic 
neuropathies. Diabetes Care, Vol. 27, No. 6, pp. 1458-86; ISSN 0149-5992. 
[15] Brownlee, M., Cerami, A., & Vlassara, H. (1988). Advanced glycosylation end products 
in tissue and the biochemical basis of diabetic complications. The New England 
Journal of Medicine, Vol.318, No.20, pp. 1315-21, ISSN 0028-4793. 
[16] Bucala, R., Tracey, K.J., & Cerami, A. (1991). Advanced glycosylation products quench 
nitric oxide and mediate defective endothelium-dependent vasodilatation in 
experimental diabetes. The Journal of Clinical Investigation, Vol. 87, No. 2, pp. 432-8, 
ISSN 0021-9738. 
[17] Cárdenas-León, M., Díaz-Díaz, E., Argüelles-Medina, R., Sánchez-Canales, P., Díaz-
Sánchez, V., & Larrea, F. (2009). Glycation and protein crosslinking in the diabetes 
and ageing pathogenesis. Revista de Investigación Clínica. Vol. 61, No. 6, pp. 505-520, 
(online), www.imbiomed.com.mx, ISSN 0034-8376.   
[18] Carneiro, F.S., Giachini, F.R., Lima, V.V., Carneiro, Z.N., Leite, R., Inscho, E.W., Tostes, 
R.C., & Webb, R.C. (2008).  Adenosine actions are preserved in corpus cavernosum 
from obese and type II diabetic db/db mouse. The Journal of Sexual Medicine, Vol. 5, 
No. 5, pp. 1156-66, ISSN 1743-6095. 
[19] Cartledge, J.J., Eardley, I., & Morrison, J.F. (2001a). Nitric oxide-mediated corpus 
cavernosal smooth muscle relaxation is impaired in ageing and diabetes.  British 
Journal of Urology International, Vol. 87, No. 4, pp. 394-401, ISSN 1464-4096. 
[20] Cartledge, J.J., Eardley, I., & Morrison, J.F. (2001b). Advanced glycation end-products 
are responsible for the impairment of corpus cavernosal smooth muscle relaxation 
seen in diabetes. British Journal of urology international, Vol. 87, No. 4, pp. 402-7, 
ISSN 1464-4096. 
[21] Cellek, S., Qu, W., Schmidt, A.M., & Moncada, S. (2004). Synergistic action of advanced 
glycation end products and endogenous nitric oxide leads to neuronal apoptosis in 
vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia, Vol. 
47, No. 2, pp. 331-9, ISSN 0012-186X. 
[22] Cellek, S., Rodrigo, J., Lobos, E., Fernandez, P., Serrano, J., & Moncada, S. (1999). 
Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-
dependent phenomenon. British Journal of Pharmacology, Vol. 128, No. 8, pp. 1804-
12, ISSN 0007-1188. 
[23] Chai, S.J., Barrett-Connor, E., & Gamst, A. (2009) Small-vessel lower extremity arterial 
disease and erectile dysfunction: The Rancho Bernardo study. Atherosclerosis, Vol. 
203, No. 2, pp. 620-5, ISSN 0021-9150. 
[24] Chang, S., Hypolite, J.A., Changolkar, A., Wein, A.J., Chacko, S., & DiSanto, M.E. (2003). 
Increased contractility of diabetic rabbit corpora smooth muscle in response to 
endothelin is mediated via Rho-kinase beta. International Journal of Impotence 
Research, Vol. 15, No. 1, pp. 53-62, ISSN 0955-9930. 
[25] Chen, D., Shan, Y.X., & Dai, Y.T. (2008). Advanced glycation end products and their 
receptors elevate the activity of endothelin-1 in rat cavernosum. Zhonghua Nan Ke 
Xue, Vol. 14, No. 2, pp. 110-5, ISSN 1009-3591. 
[26] Chitaley, K. (2009). Type 1 and Type 2 diabetic-erectile dysfunction: same diagnosis 
(ICD-9), different disease?. The Journal of Sexual Medicine, Vol. 6, No. Supplement 3, 
pp. 262-8, ISSN 1743-6095. 
[27] Chitaley, K., Kupelian, V., Subak, L., & Wessells, H. (2009). Diabetes, obesity and 
erectile dysfunction: field overview and research priorities. The Journal of Urology, 
Vol. 182, No. 6 Suppl, pp. S45-50, ISSN 0022-5347. 
www.intechopen.com
 Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus 
 
91 
[28] Cirino, G., Fusco, F., Imbimbo, C., & Mirone, V. (2006). Pharmacology of erectile 
dysfunction in man. Pharmacology & Therapeutics, Vol. 111, No. 2, pp. 400-23, ISSN 
0163-7258. 
[29] Colakoglu, Z., Kutluay, E., Ertekin, C., Altay, B., Killi, R., & Alkis, A. (1999). Autonomic 
nerve involvement and venous leakage in diabetic men with impotence. British 
Journal of Urology International, Vol. 83, No. 4, pp. 453-6, ISSN 1464-4096. 
[30] Costa, C., & Vendeira, P. (2007). The penis and endothelium. Extragenital aspects of 
erectile dysfunction. Revista Internacional de Andrología, Vol. 5, No. 1, pp. 50-8, ISSN 
1698-031X. 
[31] Costabile, R.A. (2003) Optimizing treatment for diabetes mellitus induced erectile 
dysfunction. The Journal of Urology, Vol. 170, No. 2 Pt 2, pp. S35-8; discussion S39, 
ISSN 0022-5347. 
[32] Cox, J.D., Kim, N.N., Traish, A.M., & Christianson, D.W. (1999). Arginase-boronic acid 
complex highlights a physiological role in erectile function. Nature Structural 
Biology, Vol. 6, No. 11,  pp. 1043-7, ISSN 1072-8368. 
[33] De Angelis, L., Marfella, M.A., Siniscalchi, M., Marino, L., Nappo, F., Giugliano, F., De 
Lucia, D., & Giugliano, D. (2001). Erectile and endothelial dysfunction in Type II 
diabetes: a possible link. Diabetologia, Vol. 44, No. 9, pp. 1155-60, ISSN 0012-186X. 
[34] Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, 
P. (2004). Frequent occurrence of hypogonadotropic hypogonadism in type 2 
diabetes. The Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 11, pp. 
5462-8, ISSN 0021-972X. 
[35] Eardley, I. (2002). Pathophysiology of erectile dysfunction. British Journal of Diabetes and 
Vascular Disease, Vol. 2, No. 4, pp. 272-6, ISSN 1474-6514.  
[36] Elías-Calles, L.C., & Licea M.E. (2003). Disfunción  sexual eréctil y diabetes mellitus. 
Aspectos etiopatogénicos. Revista Cubana de Endocrinología, Vol. 14, No. 2, (online), 
http://bvs.sld.cu/revistas/end/vol14_2_03/end07203.htm, ISSN 1561-2953. 
[37] England, J.D., & Asbury, A.K. (2004). Peripheral neuropathy. The Lancet, Vol. 363, No. 
9427, pp. 2151-61, ISSN 0140-6736. 
[38] Fabbri, A., Aversa, A., & Isidori, A. (1997). Erectile dysfunction: an overview. Human 
Reproduction Update, Vol. 3, No. 5, pp. 455-66, ISSN 1355-4786. 
[39] Fedele, D., Bortolotti, A., Coscelli, C., Santeusanio, F., Chatenoud, L., Colli, E., 
Lavezzari, M., Landoni, M., & Parazzini, F. (2000). Erectile dysfunction in type 1 
and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei 
Diabetici. International Journal of Epidemiology, Vol. 29, No. 3, pp. 524-31, ISSN 0300-
5771. 
[40] Fedele, D., Coscelli, C., Cucinotta, D., Forti, G., Santeusanio, F., Viaggi, S., Fiori, G., 
Velona, T., & Lavezzari, M. (2001). Incidence of erectile dysfunction in Italian men 
with diabetes. The Journal of Urology, Vol. 166, No. 4, pp. 1368-71, ISSN 0022-5347. 
[41] Feldman, H.A., Goldstein, I., Hatzichristou, D.G., Krane, R.J., & McKinlay, J.B. (1994). 
Impotence and its medical and psychosocial correlates: results of the Massachusetts 
Male Aging Study. The Journal of Urology, Vol. 151, No. 1, pp. 54-61, ISSN 0022-5347. 
[42] Ganz, M.B., & Seftel, A. (2000). Glucose-induced changes in protein kinase C and nitric 
oxide are prevented by vitamin E. American Journal of Physiology - Endocrinology and 
Metabolism, Vol. 278, No. 1, pp. E146-52, ISSN 0193-1849. 
[43] Grossmann, M., Thomas, M.C., Panagiotopoulos, S., Sharpe, K., Macisaac, R.J., Clarke, 
S., Zajac, J.D., & Jerums, G. (2008). Low testosterone levels are common and 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
92
associated with insulin resistance in men with diabetes. The Journal of Clinical 
Endocrinology and Metabolism, Vol. 93, No. 5, pp. 1834-40, ISSB 0021-972X. 
[44] Gur, S., Kadowitz, P.J. , & Hellstrom, W.J. (2009). A critical appraisal of erectile function 
in animal models of diabetes mellitus. International Journal of Andrology, Vol. 32, No. 
2, pp. 93-114, ISSN 0105-6263. 
[45] Hermans, M.P., Ahn, S.A., & Rousseau, M.F. (2009).  Erectile dysfunction, 
microangiopathy and UKPDS risk in type 2 diabetes. Diabetes & Metabolism, Vol. 35, 
No. 6, pp. 484-9, ISSN 1262-3636. 
[46] Hidalgo-Tamola, J., & Chitaley, K. (2009). Review type 2 diabetes mellitus and erectile 
dysfunction. The Journal of Sexual Medicine, Vol. 6, No. 4, pp. 916-26, ISSN 1743-6095. 
[47] Jeremy, J.Y., Angelini, G.D., Khan, M., Mikhailidis, D.P., Morgan, R.J., Thompson, C.S., 
Bruckdorfer, K.R., & Naseem, K.M. (2000). Platelets, oxidant stress and erectile 
dysfunction: an hypothesis. Cardiovascular Research, Vol. 46, No. 1, pp. 50-4, ISSN 
0008-6363. 
[48] Jesmin, S., Sakuma, I., Salah-Eldin, A., Nonomura, K., Hattori, Y., & Kitabatake, A. 
(2003). Diminished penile expression of vascular endothelial growth factor and its 
receptors at the insulin-resistant stage of a type II diabetic rat model: a possible 
cause for erectile dysfunction in diabetes. Journal of Molecular Endocrinology, Vol. 31, 
No. 3, pp. 401-18, ISSN 0952-5041. 
[49] Jiaan, D.B., Seftel, A.D., Fogarty, J., Hampel, N., Cruz, W., Pomerantz, J., Zuik, M., & 
Monnier, V.M. (1995). Age-related increase in an advanced glycation end product 
in penile tissue. World Journal of Urology, Vol. 13, No. 6, pp. 369-75, ISSN 0724-4983. 
[50] Johannes, C.B., Araujo, A.B., Feldman, H.A., Derby, C.A., Kleinman, K.P., & McKinlay, 
J.B. (2000). Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal 
results from the Massachusetts male aging study. The Journal of Urology, Vol. 163, 
No. 2, pp. 460-3, ISSN 0022-5347. 
[51] Kadioglu, A., Memisoglu, K., Sazova, O., Erdogru, T., Karsidag, K., & Tellaloglu, S. 
(1994). The effects of diabetes on penile somato-afferent system. Archivos Españoles 
de Urología, Vol. 47, No. 1, pp. 100-3, ISSN 0004-0614. 
[52] Kapoor, D., Aldred, H., Clark, S., Channer, K.S., & Jones, T.H. (2007). Clinical and 
biochemical assessment of hypogonadism in men with type 2 diabetes: correlations 
with bioavailable testosterone and visceral adiposity. Diabetes Care, Vol. 30, No. 4, 
pp. 911-7, ISSN 1935-5548. 
[53] Kasiske, B.L., O'Donnell, M.P., & Keane, W.F. (1992). The Zucker rat model of obesity, 
insulin resistance, hyperlipidemia, and renal injury. Hypertension, Vol. 19, No. 1 
Supplement, pp. I110-5, ISSN 0194-911X. 
[54] Kawano, K., Hirashima, T., Mori, S., Saitoh, Y., Kurosumi, M., & Natori, T. (1992) 
Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka 
Long-Evans Tokushima Fatty (OLETF) strain. Diabetes, Vol. 41, No. 11, pp. 1422-8, 
ISSN 0012-1797. 
[55] Khatana, S.A., Taveira, T.H., Miner, M.M., Eaton, C.B., & Wu, W.C. (2008). Does 
cardiovascular risk reduction alleviate erectile dysfunction in men with type II 
diabetes mellitus?. International Journal of Impotence Research, Vol. 20, No. 5, pp. 
501-6, ISSN 0955-9930. 
[56] Klein, R., Klein, B.E., Lee, K.E., Moss, S.E., & Cruickshanks, K.J. (1996). Prevalence of 
self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care, 
Vol. 19, No. 2, pp. 135-41, ISSN 0149-5992. 
www.intechopen.com
 Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus 
 
93 
[57] Kleinman, K.P., Feldman, H.A., Johannes, C.B., Derby, C.A., & McKinlay, J.B. (2000). A 
new surrogate variable for erectile dysfunction status in the Massachusetts male 
aging study. Journal of Clinical Epidemiology, Vol. 53, No. 1, pp. 71-8. ISSN 0895-
4356. 
[58] Kubin, M., Wagner, G., & Fugl-Meyer, A.R. (2003). Epidemiology of erectile 
dysfunction. International Journal of Impotence Research, Vol. 15, No. 1, pp. 63-71, 
ISSN 0955-9930. 
[59] Kumar, V., Madhu, S.V., Singh, G., & Gambhir, J.K. (2010). Post-prandial 
hypertriglyceridemia in patients with type 2 diabetes mellitus with and without 
macrovascular disease. The Journal of the Association of Physicians of India, Vol. 58, 
p.p. 603-7, ISSN 0004-5772. 
[60] Laumann, E.O., Paik, A., & Rosen, R.C. (1999). Sexual dysfunction in the United States: 
prevalence and predictors. The Journal of the American Medical Association, Vol. 281, 
No. 6, pp. 537-44, ISSN 0098-7484. 
[61] Li, X.X., Qiu, X.F., Yu, W., Zhu, W.D., Chen, Y., & Dai, Y.T. (2011). Mechanisms of 
oxidative stress-induced damage and its protection in cavernous mitochondria of 
diabetic rats. Beijing Da Xue Xue Bao, Vol. 43, No. 2, p.p. 189-93, ISSN 1671-167X. 
[62] Lundberg, P.O., Ertekin, C., Ghezzi, A., Swash, M., & Vodusek, D. (2001). 
Neurosexology. Guidelines for Neurologists: European Federation of Neurological 
Societies Task Force on Neurosexology. European Journal of Neurology, Vol. 8, No. 
Supplement 3, pp. 2-24, ISSN 1351-5101. 
[63] Luttrell, I.P., Swee, M., Starcher, B., Parks, W.C., & Chitaley, K. (2008). Erectile 
dysfunction in the type II diabetic db/db mouse: impaired venoocclusion with 
altered cavernosal vasoreactivity and matrix. American Journal of Physiology Heart 
and Circulatory Physiology, Vol. 294, No. 5, pp. H2204-11, ISSN 0363-6135. 
[64] Maas, R., Schwedhelm, E., Albsmeier, J., & Boger, R.H. (2002). The pathophysiology of 
erectile dysfunction related to endothelial dysfunction and mediators of vascular 
function. Vascular Medicine, Vol. 7, No. 3, pp. 213-25, ISSN 1358-863X. 
[65] Martin-Morales, A., Sanchez-Cruz, J.J., Saenz de Tejada, I., Rodriguez-Vela, L., Jimenez-
Cruz, J.F., & Burgos-Rodriguez, R. (2001). Prevalence and independent risk factors 
for erectile dysfunction in Spain: results of the Epidemiología de la Disfunción 
Eréctil Masculina Study. The Journal of Urology, Vol. 166, No. 2, pp. 569-74; 
discussion 574-5, ISSN 0022-5347. 
[66] Mc Vary, K.Y., Podlasek, C.A., McKenna, K.E., & Wood, D. (2006). Intrinsic and 
extrinsic apoptotic pathways are employed in neuropathic and diabetic models of 
erectile dysfunction. The Journal of Sexual Medicine, Vol. 3, No. Supplement 1, pp. 45, 
ISSN 1743-6095. 
[67] McCulloch, D.K., Campbell, I.W., Wu, FC., Prescott, R.J., & Clarke, B.F. (1980). The 
prevalence of diabetic impotence. Diabetologia, Vol. 18, No. 4, pp. 279-83, ISSN 0012-
186X. 
[68] McMurray, G., Casey, J.H. & Naylor, A.M.  (2006). Animal models in urological disease 
and sexual dysfunction British Journal of Pharmacology, Vol. 147, No. Supplement 2, 
pp. S62-79, ISSN 0007-1188. 
[69] Meena, B.L., Kochar, D.K., Agarwal, T.D., Choudhary, R., & Kochar, A. (2009). 
Association between erectile dysfunction and cardiovascular risk in individuals 
with type-2 diabetes without overt cardiovascular disease. International Journal of 
Diabetes in Developing Countries, Vol. 29, No. 4,  pp. 150-4, ISSN 1998-3832. 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
94
[70] Metro, M.J. & Broderick, G.A. (1999). Diabetes and vascular impotence: does insulin 
dependence increase the relative severity?. International Journal of Impotence 
Research, Vol. 11, No. 2, pp. 87-9, ISSN 0955-9930. 
[71] Miccoli, R., Giampietro, O., Tognarelli, M., Rossi, B., Giovannitti, G., & Navalesi, R. 
(1987).  Prevalence and type of sexual dysfunctions in diabetic males: a 
standardized clinical approach. Journal of Medicine, Vol. 18, No. 5-6, pp. 305-21, 
ISSN 0025-7850. 
[72] Mills, T.M., Chitaley, K., Lewis, R.W., & Webb, R.C. (2002). Nitric oxide inhibits 
RhoA/Rho-kinase signaling to cause penile erection. European Journal of 
Pharmacology, Vol. 439, No. 1-3, pp. 173-4, ISSN 0014-2999. 
[73] Moore, C.R. & Wang, R. (2006). Pathophysiology and treatment of diabetic erectile 
dysfunction. Asian Journal of Andrology, Vol. 8, No. 6, pp. 675-84, ISSN 1008-682X. 
[74] Morano, S. (2003). Pathophysiology of diabetic sexual dysfunction. Journal of 
Endocrinology Investigation, Vol. 26, No. Supplement 3, pp. 65-9, ISSN 0391-4097. 
[75] Morley, J.E. (1986). Impotence. The American Journal of Medicine, Vol. 80, No. 5, pp. 897-
905. ISSN 0002-9343.  
[76] Musicki, B. & Burnett, A.L. (2006). eNOS function and dysfunction within the penis. 
Experimental Biology and Medicine, Vol. 231, No. 2, pp. 154-65, ISSN 1535-3702. 
[77] National Institutes of Health (NIH) Consensus Conference. (1993). Impotence. NIH 
Consensus Development Panel on Impotence. The Journal of the American Medical 
Association,  Vol. 270, No. 1, pp. 83-90, ISSN 0098-7484. 
[78] Osuna, J.A., Gomez-Perez, R., Arata-Bellabarba, G., & Villaroel, V. (2006). Relationship 
between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and 
insulin resistance in obese men. Archives of Andrology, Vol. 52, No. 5, pp. 355-61, 
ISSN 0148-5016. 
[79] Pasquali, R., Macor, C., Vicennati, V., Novo, F., De lasio, R., Mesini, P., Boschi, S., 
Casimirri, F., & Vettor, R.  (1997). Effects of acute hyperinsulinemia on testosterone 
serum concentrations in adult obese and normal-weight men. Metabolism, Vol. 46, 
No. 5, pp. 526-9, ISSN 0026-0495. 
[80] Pitteloud, N., Hardin, M., Dwyer, A.A., Valassi, E., Yialamas, M., Elahi, D., & Hayes, F.J. 
(2005). Increasing insulin resistance is associated with a decrease in Leydig cell 
testosterone secretion in men. The Journal of Clinical Endocrinology and Metabolism, 
Vol. 90, No. 5, pp. 2636-41, ISSN 0021-972X. 
[81] Rhoden, E.L., Ribeiro, E.P., Teloken, C., & Souto, C.A. (2005). Diabetes mellitus is 
associated with subnormal serum levels of free testosterone in men. British Journal 
of Urology International, Vol. 96, No. 6, pp. 867-70, ISSN 1464-4096. 
[82] Ritchie, R. & Sullivan, M. (2010). Endothelins & erectile dysfunction. Pharmacological 
Research, Vol. 63, No. 6, pp. 496-501, ISSN 1096-1186. 
[83] Romeo, J.H., Seftel, A.D., Madhun, Z.T., & Aron, D.C. (2000). Sexual function in men 
with diabetes type 2: association with glycemic control. The Journal of Urology, Vol. 
163, No. 3, pp. 788-91, ISSN 0022-5347. 
[84] Romero, J.C., Hernández, A., Licea, M.E., & Márquez, A. (1997). Evaluación 
electrofisiológica, vascular y hormonal en diabéticos tipo 1 con disfunción sexual 
eréctil. Revista de la Asociación Latinoamericana de Diabetes, Vol. 3, pp. 147-53, ISSN 
0327-9154. 
[85] Roth, A., Kalter-Leibovici, O., Kerbis, Y., Tenenbaum-Koren, E., Chen, J., Sobol, T., & 
Raz, I. (2003). Prevalence and risk factors for erectile dysfunction in men with 
www.intechopen.com
 Erectile Dysfunction: A Chronic Complication of the Diabetes Mellitus 
 
95 
diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli 
men. Clinical Cardiology, Vol. 26, No. 1, pp. 25-30, ISSN 0160-9289. 
[86] Saenz de Tejada, I., Goldstein, I., Azadzoi, K., Krane, R.J., & Cohen, R.A. (1989). 
Impaired neurogenic and endothelium-mediated relaxation of penile smooth 
muscle from diabetic men with impotence. The New England Journal of Medicine, Vol. 
320, No. 16, pp. 1025-30, ISSN 0028-4793. 
[87] Saigal, C.S., Wessells, H., Pace, J., Schonlau, M., & Wilt, T.J. (2006). Predictors and 
prevalence of erectile dysfunction in a racially diverse population. Archives of 
Internal Medicine, Vol. 166, No. 2, pp. 207-12, ISSN 0003-9926. 
[88] Seftel, A.D., Vaziri, N.D., Ni, Z., Razmjouei, K., Fogarty, J., Hampel, N., Polak, J., Wang, 
R.Z., Ferguson, K., Block, C., & Haas, C. (1997). Advanced glycation end products 
in human penis: elevation in diabetic tissue, site of deposition, and possible effect 
through iNOS or eNOS. Urology, Vol. 50, No. 6, pp. 1016-26, ISSN 0090-4295. 
[89] Sharma, K., McCue, P. & Dunn, S.R. (2003). Diabetic kidney disease in the db/db 
mouse. The American Journal of Physiology: Renal Physiology, Vol. 284, No. 6, pp. 
F1138-44, ISSN 0363-6127. 
[90] Singh, R., Barden, A., Mori, T., & Beilin, L. (2001). Advanced glycation end-products: a 
review. Diabetologia, Vol. 44, No. 2, pp. 129-46, ISSN 0012-186X. 
[91] Soderberg, S., Olsson, T., Eliasson, M., Johnson, O., Brismar, K., Carlstrom, K., & Ahren, 
B. (2001). A strong association between biologically active testosterone and leptin in 
non-obese men and women is lost with increasing (central) adiposity. International 
Journal of Obesity and Related Metabolic Disorders, Vol. 25, No. 1, pp. 98-105, ISSN 
0307-0565. 
[92] Sullivan, M.E., Dashwood, M.R., Thompson, C.S., Muddle, J.R., Mikhailidis, D.P., & 
Morgan, R.J. (1997). Alterations in endothelin B receptor sites in cavernosal tissue 
of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. 
The Journal of Urology, Vol. 158, No. 5, pp. 1966-72, ISSN 0022-5347. 
[93] Svartberg, J. (2007). Epidemiology: testosterone and the metabolic syndrome. 
International Journal of Impotence Research, Vol. 19, No. 2, pp. 124-8, ISSN 0955-9930.  
[94] Thorve, V.S., Kshirsagar, A.D., Vyawahare, N.S., Joshi, V.S., Ingale, K.G., & Mohite, R.J. 
(2011). Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and 
management. Journal of diabetes and its complications, Vol. 25, No. 2, pp. 129-36, ISSN 
1056-8727. 
[95] Tomar, R., Dhindsa, S., Chaudhuri, A., Mohanty, P., Garg, R., & Dandona, P. (2006). 
Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care, 
Vol. 29, No. 5, pp. 1120-2, ISSN 0149-5992. 
[96] Traish, A.M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone 
deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology, 
Vol. 30, No. 1, pp. 10-22, ISSN 1939-4640. 
[97] Tripathy, D., Dhindsa, S., Garg, R., Khaishagi, A., Syed, T., & Dandona, P. (2003). 
Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 
diabetes mellitus: a common defect?. Metabolic Syndrome and Related Disorders, Vol. 
1, No. 1, pp. 75-80, ISSN 1557-8518. 
[98] Usta, M.F., Bivalacqua, T.J., Koksal, I.T., Toptas, B., Surmen, S., & Hellstrom, W.J. (2004). 
The protective effect of aminoguanidine on erectile function in diabetic rats is not 
related to the timing of treatment. British Journal of Urology International, Vol. 94, 
No. 3, pp. 429-32, ISSN 1464-4096. 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
96
[99] Usta, M.F., Bivalacqua, T.J., Yang, D.Y., Ramanitharan, A., Sell, D.R., Viswanathan, A., 
Monnier, V.M., & Hellstrom, W.J. (2003). The protective effect of aminoguanidine 
on erectile function in streptozotocin diabetic rats. The Journal of Urology, Vol. 170, 
No. 4 Pt 1, pp. 1437-42, ISSN 0022-5347. 
[100] Usta, M.F., Kendirci, M., Gur, S., Foxwell, N.A., Bivalacqua, T.J., Cellek, S., & 
Hellstrom, W.J. (2006). The breakdown of preformed advanced glycation end 
products reverses erectile dysfunction in streptozotocin-induced diabetic rats: 
preventive versus curative treatment. The Journal of Sexual Medicine, Vol. 3, No. 2, 
pp. 242-50; discussion 250-2, ISSN 1743-6095. 
[101] Vernet, D., Cai, L., Garban, H., Babbitt, M.L., Murray, F.T., Rajfer, J., & Gonzalez-
Cadavid, N.F. (1995). Reduction of penile nitric oxide synthase in diabetic 
BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. 
Endocrinology, Vol. 136, No. 12, pp. 5709-17, ISSN 0013-7227. 
[102]  Vignozzi, L., Corona, G., Petrone, L., Filippi, S., Morelli, A.M., Forti, G., & Maggi, M. 
(2005). Testosterone and sexual activity. Journal of Endocrinological Investigation, Vol. 
28, No. supplement 3, pp. 39-44, ISSN 0391-4097. 
[103] Vignozzi, L., Morelli, A., Filippi, S., Ambrosini, S., Mancina, R., Luconi, M., Mungai, S., 
Vannelli, G.B., Zhang, X.H., Forti, G., & Maggi, M. (2007). Testosterone regulates 
RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. 
The Journal of Sexual Medicine, Vol. 4, No. 3, pp. 620-30; discussion 631-32. ISSN 
1743-6095. 
[104] Werner, M.E., Meredith, A.L., Aldrich, R.W., & Nelson, M.T. (2008). Hypercontractility 
and impaired sildenafil relaxations in the BKCa channel deletion model of erectile 
dysfunction. American Journal of Physiology-Regulatory, Integratives and Comparative 
Physiology, Vol. 295, No. 1, pp. R181-8, ISSN 0363-6119. 
[105] Wingard, C., Fulton, D., & Husain, S. (2007). Altered penile vascular reactivity and 
erection in the Zucker obese-diabetic rat. The Journal of Sexual Medicine, Vol. 4, No. 
2, pp. 348-62; discussion 362-3, ISSN 1743-6095. 
[106] World Health Organization. (2000). Erectil Dysfunction. Health Publication Ltd. 
Plymouth. Oxford. United Kindom.  
[107] Xie, D., Odronic, S.I., Wu, F., Pippen, A., Donatucci, C.F., & Annex, B.H. (2007). Mouse 
model of erectile dysfunction due to diet-induced diabetes mellitus. Urology, Vol. 
70, No. 1, pp. 196-201, ISSN 1527-9995. 
[108] Yassin, A.A. & Saad, F. (2008). Testosterone and erectile dysfunction. Journal of 
Andrology, Vol. 29, No. 6, pp. 593-604, ISSN 1939-4640. 
[109] Yildirim, S., Ayan, S., Sarioglu, Y., Gultekin, Y., & Butuner, C. (1999). The effects of 
long-term oral administration of L-arginine on the erectile response of rabbits with 
alloxan-induced diabetes. British Journal of Urology International, Vol. 83, No. 6, pp. 
679-85, ISSN 1464-4096. 
www.intechopen.com
Erectile Dysfunction - Disease-Associated Mechanisms and Novel
Insights into Therapy
Edited by Dr. Kenia Nunes
ISBN 978-953-51-0199-4
Hard cover, 214 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Erectile dysfunction is a widespread problem, affecting many men across all age groups and it is more than a
serious quality of life problem for sexually active men. This book contains chapters written by widely
acknowledged experts, each of which provides a unique synthesis of information on emergent aspects of ED.
All chapters take into account not only the new perspectives on ED but also recent extensions of basic
knowledge that presage directions for further research. The approach in this book has been to not only
describe recent popular aspects of ED, such as basic mechanism updates, etiologic factors and
pharmacotherapy, but also disease-associated ED and some future perspectives in this field.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Eulises Díaz-Díaz, Mario Cárdenas León, Nesty Olivares Arzuaga, Carlos M. Timossi, Rita Angélica Gómez
Díaz, Carlos Aguilar Salinas and Fernando Larrea (2012). Erectile Dysfunction: A Chronic Complication of the
Diabetes Mellitus, Erectile Dysfunction - Disease-Associated Mechanisms and Novel Insights into Therapy, Dr.
Kenia Nunes (Ed.), ISBN: 978-953-51-0199-4, InTech, Available from:
http://www.intechopen.com/books/erectile-dysfunction-disease-associated-mechanisms-and-novel-insights-
into-therapy/erectile-dysfunction-a-chronic-complication-of-the-diabetes-mellitus
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
